• Prof. Dr. Fred van Eenennaam joins the Microeconomics of Competitiveness Affiliate Network Hall of Fame


    We are delighted to announce that Prof. Dr. Fred van Eenennaam, partner of The Decision Group, has been put in the limelight by Prof. Dr. Michael Porter. Because of his contribution to the pragmatics of and research in the competitiveness of clusters, as well as his extensive involvement in the worldwide MOC network, Prof. Dr. Fred van Eenennaam is now included in the Microeconomics of Competitiveness Affiliate Network Hall of Fame. We are proud of this unexpected honour, and we see it as an encouragement to continue to offer our expertise to all who can use it to their advantage.

    Visit our dedicated website to learn more on Competitiveness & Clusters!

    The Netherlands Institute for Competitiveness

    Furthermore, we are pleased and excited to announce that in December 2012, we have launched the Netherlands Institute for Competitiveness. The Institute could not have been established without the help from our international academic colleagues. It is the logical consequence of the experiences in the past. The center combines the international network of cluster organizations with academic and pragmatic expertise on international business. The aim of the Netherlands Institute for Competitiveness is to provide expertise, access and knowledge to 1) companies that wish to build their international business and 2) academic institutes that wish to increase their knowledge.

    We invite you to take a look at our website.

    Continue reading
  • Prosensa – Dutch biotech success

    Prosensa is a succesful biotech company in the Dutch Life Sciences Cluster. In January 2012 it closed the Series C round and raised another $30 million, by a large international investor.  Prosensa has grown from a small startup to a renowned Dutch biotech company in the development of a treatment from “bench to bed” for orphan diseases.

    Partner The Decision Institute has written a Harvard Style Business Case about the company and its search for a treatment for Duchenne Muscular Dystrophy, a rare genetic disorder. The objective is to demonstrate the best practices of the Dutch biotech cluster. What can we learn from Prosensa and the biotech cluster? What are their strategies to bind large investors? Thanks to Leiden University, LSH, LUMC, NGI, PGGM, Prosensa, The Decision Institute and expecially all interviewees and editors who made it possible to develop the The Prosensa Case; Pioneering & Partnering. The case and the experiences of The Decision Group can help you to bind international partnerships for your strategic next steps.  

    Biotech and The Decision Group.

    Since 1998,  extensive expertise is built in biotech and life sciences. Out portfolio contains a wide range of projects for big pharma, medical device companies and biotech companies. Scenario analysis and strategic reviews as well as helping  to create patient centered relations with customers and realizing growthpotential in the cost-cutting market..
    Furthermore, The Decision Group monitors clusters success in Life Sciences & Health. The Dutch Life Sciences & Health Outlook measures performance and progress of the industry and benchmarks with succesful clusters worldwide. The aim of the Outlook 2013 is also to address the convergence to healthcare. Innovation from Bench to Bed.

    • Learn more on scenario planning and cluster monitoring by visiting the website advanced strategic tools.
    • Request your copy of the Dutch Life Sciences Outlook here.
    • Send an e-mail to Kim Bruheim to learn more on the possibilities with the new case.
    • See also:

    The Decision Group:
    Consulting on Competitiveness & Clusters
    Consulting on Life Sciences
    Dutch Life Science Outlook

    The Decision Institute: Clusters and Competitiveness:
    The Netherlands Institute of Competitiveness
    Microeconomics of Competitiveness

    Executive programs:
    Strategy & Governance Excellence Series

    Continue reading
  • Dutch Life Sciences Outlook 2012 released

    On Wednesday January 18th, Prof. dr. F. van Eenennaam, partner of The Decision Group, presented the Dutch Life Sciences Outlook for a group of  60 key stakeholders in Life Sciences. The Outlook yearly monitors Dutch Life Sciences & Health Cluster success and measures  performance and progress of the sector. This yearly systematic Outlook is created in close collaboration between The Decision Group and Life Sciences Health.

    Clusters & Competitiveness

    Prior to presenting the Outlook, Prof dr. F. van Eenennaam gave a Masterclass on Cluster Development, where theory and practicalities of clusters were discussed, as well as implications for Dutch policy makers. The Decision Group has extensive expertise on Clusters & Competitiveness. See also our Clusters & Competitiveness website

    The Dutch Life Sciences Outlook 2012 can be downloaded from our dedicated website www.lifesciencesoutlook.com.

    Continue reading
  • Decision Group methodology part of topsector Life Science & Health plan

    Plans for the Dutch topsectors LSH sector presented to Minister Verhagen

    The 9 topsectors the Dutch government has assigned presented their individual sectorplans to the minister of Economic Affairs on friday June 17th.  Life Sciences and Health is one of the 9 topsectors that presented their ambition and action agenda for the next 10-15 years. To measure progress on the action agenda, the methodology developed by The Decision Group together with Life Science & Health innovationprogramme is mentioned.

    Measuring methodology

    The methodology that was developed by The Decision Group to monitor the performance and progress in the Dutch Life Sciences & Health (LSH) sector has been acknowledged by the topsector. Our data on the core of innovative companies in the Dutch cluster was used to indicate the size and output of the cluster. And moreover, the way we measure the size, in-  and output of the Dutch LSH cluster  is seen as a proven methodology to monitor progress of the cluster’s ambition and agenda and provides a baseline for measuring progress in the next years.

    To request a copy of the Dutch Life Sciences Outlook 2011, click here.

    To read more on the Dutch Life Sciences Outlook, see here.

    Click the picture to enlarge.

    Continue reading